123 related articles for article (PubMed ID: 38599640)
1. [The efficacy and safety of immunotherapy combined with chemotherapy neoadjuvant in locally advanced resectable hypopharyngeal squamous cell carcinoma].
Wang K; Zhang W; Gui L; He XH; Wang JB; Lu HZ; Li DZ; Liu C; Guo ZZ; Xu M; Liu SY; Wang XL
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):343-349. PubMed ID: 38599640
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas.
Wang K; Gui L; Lu H; He X; Li D; Liu C; Liu S; Wang X
Front Immunol; 2023; 14():1189752. PubMed ID: 37583698
[TBL] [Abstract][Full Text] [Related]
3. [Significance of neoadjuvant immunotherapy combined with chemotherapy in the treatment of larynx preservation in locally advanced hypopharyngeal squamous cell carcinoma].
Wu J; Hu G; Li M; Wang Z; Ma W; Wang X; Zhu J; Pan M; Zeng Q
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Sep; 37(9):715-720;728. PubMed ID: 37830119
[No Abstract] [Full Text] [Related]
4. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
Wu D; Li Y; Xu P; Fang Q; Cao F; Lin H; Li Y; Su Y; Lu L; Chen L; Li Y; Zhao Z; Hong X; Li G; Tian Y; Sun J; Yan H; Fan Y; Zhang X; Li Z; Liu X
Nat Commun; 2024 Mar; 15(1):2177. PubMed ID: 38467604
[TBL] [Abstract][Full Text] [Related]
5. [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
[No Abstract] [Full Text] [Related]
6. PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study.
Fang Q; Xu P; Cao F; Wu D; Liu X
Cancer Immunol Immunother; 2023 Dec; 72(12):4161-4168. PubMed ID: 37804437
[TBL] [Abstract][Full Text] [Related]
7. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
8. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
9. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
Zhang Z; Wu B; Peng G; Xiao G; Huang J; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Hong X; Wei J; Qin Y; Wan C; Zhong Y; Zhou Y; Zhao X; Leng Y; Zhang T; Wu G; Yao M; Zhang X; Yang K
Clin Cancer Res; 2022 Aug; 28(15):3268-3276. PubMed ID: 35766967
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
[TBL] [Abstract][Full Text] [Related]
12. Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial.
Ou X; Zhai R; Wei W; Chen J; Ou D; Liao T; Xu T; Zhu Y; Wang Y; Huang S; Shi R; Wu B; Chen T; Li Y; Yang Z; Zhou C; Liu Y; Jiang Z; Zeng M; Liu X; Ji D; Ying H; Zhang Z; Hu C; Lu X; Ji Q; He X; Wang Y
Clin Cancer Res; 2024 Jan; 30(2):344-355. PubMed ID: 37955629
[TBL] [Abstract][Full Text] [Related]
13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck.
Weiss JM; Grilley-Olson JE; Deal AM; Zevallos JP; Chera BS; Paul J; Knowles MF; Usenko D; Weissler MC; Patel S; Hayes DN; Hackman T
Cancer; 2018 Jul; 124(14):2986-2992. PubMed ID: 29741773
[TBL] [Abstract][Full Text] [Related]
15. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients.
Tang AL; O'Neil T; McDermott S; Tripathi S; Tikhtman R; Mark JR; Patil Y; Tabangin M; Altaye M; Wise-Draper TM; Zender CA
JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):935-939. PubMed ID: 36006622
[TBL] [Abstract][Full Text] [Related]
16. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
17. Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma.
Peng J; Luo G; Yu Y; Ning K; Liu X
Cancer Immunol Immunother; 2024 Feb; 73(3):54. PubMed ID: 38358522
[TBL] [Abstract][Full Text] [Related]
18. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.
Li C; Yu P; Li H; Yang X; Wang J; Jiang B
J Cardiothorac Surg; 2024 Jan; 19(1):26. PubMed ID: 38273405
[TBL] [Abstract][Full Text] [Related]
19. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).
Ding C; Guo Y; Zhou Y; He Y; Chen C; Zhang M; Guo X
BMC Cancer; 2023 Dec; 23(1):1237. PubMed ID: 38102553
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]